All the Guidance They Need: Biosimilars Business Development Doesn't Wait For FDA
This article was originally published in RPM Report
Executive Summary
Wall Street is eagerly awaiting formal guidance from FDA on the new biosimilar pathway in the US. Biotech companies large and small aren't waiting.
You may also be interested in...
Biosimilars: Inverting the Innovator Development Model
When it comes to the new biosimilar pathway, it’s the IND—not the BLA—that matters.
Biogen Tests Biosimilars Waters In Joint Venture With Samsung
A joint venture with Korean conglomerate Samsung will be limited to making generic versions of non-Biogen products, although Samsung separately is working on a biosimilar of rituximab.
FDA's Biosimilar Strategy Will Rely On "Fingerprint" Technology To Limit Trials
European experiences with "totality of the evidence" method also seem to be shaping policy, according to FDA article in NEJM.